Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07243275 · ClinicalTrials.gov registry record · Phase 4
SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease
A Phase 4 study, sponsored by Indiana University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 260
- Enrollment target
NCT07243275: Recruiting Phase 4 study, sponsored by Indiana University.
NCT07243275 is a Phase 4 study that is actively recruiting participants, run by Indiana University. The registered enrollment target is 260 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07243275, a Phase 4 study, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 260 participants
- Enrollment target
Study Summary
This is a prospective, randomized, double-masked, multi-site clinical trial designed to compare the efficacy of SYSTANE® PRO (Alcon Laboratories, Inc.) to MIEBO™ (Bausch + Lomb) in treating symptoms of evaporative dry eye disease (DED). The primary goal is to determine whether SYSTANE® PRO is non-inferior to MIEBO™ after one month of treatment, based on change in Ocular Surface Disease Index (OSDI) scores.
Primary Outcome
Between-group difference in mean change from baseline in Ocular Surface Disease Index (OSDI) Scores at the 1-month visit (0-100 scale).
Interventions
- DRUG SYSTANE® PRO
- DRUG MIEBO™ (Perfluorohexyloctane, PFHO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 4 |
What NCT07243275 shows while recruiting
NCT07243275 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which SYSTANE® PRO is the first listed.
NCT07243275 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07243275 about?
NCT07243275 is a clinical study titled "SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease". This is a prospective, randomized, double-masked, multi-site clinical trial designed to compare the efficacy of SYSTANE® PRO (Alcon Laboratories, Inc.) to MIEBO™ (Bausch + Lomb) in treating symptoms of evaporative dry eye disease (DED). The primary goal is to determine whether SYSTANE® PRO is non-in...
What is the current status of trial NCT07243275?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 260 participants. The study started on 2026-02-18. Estimated completion is 2026-09-30.
What interventions are being tested in trial NCT07243275?
The interventions under investigation include: SYSTANE® PRO (DRUG), MIEBO™ (Perfluorohexyloctane, PFHO) (DRUG).
Who is sponsoring clinical trial NCT07243275?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07243275's enrollment target sits among peer trials
260 326th of 2000 higher than 1,670 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI